Nubeqa (darolutamide)
pCPA File Number:
22191
Negotiation Status:
Active Negotiation
Indication(s):
For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Sponsor/Manufacturer:
Bayer Inc.
CADTH Project Number:
PC0294
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable